NK Cell Therapies Pipeline 2025: Revolutionizing Immunotherapy Approaches

DelveInsight's "NK Cell Therapies Pipeline Insight, 2025" report offers extensive analysis on over 140 companies and more than 160 pipeline drugs in the NK Cell Therapies treatment arena. It features in-depth profiles of NK Cell Therapies pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses NK Cell Therapies therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Discover the newest medications and treatment avenues in the NK Cell Therapies Pipeline. Explore DelveInsight's thorough report now! @ NK Cell Therapies Pipeline Outlook

Key Highlights from the NK Cell Therapies Pipeline Report

On August 15, 2025, Artiva Biotherapeutics Inc. disclosed a phase 2a trial to assess the safety and effectiveness of AlloNK®, an allogeneic cord blood-derived NK cell therapy, paired with rituximab in recurring B-cell related rheumatologic conditions.
On August 12, 2025, Takeda launched a study in the US, with Part 2 extending globally. The total participation period is 5 years. Participants will attend multiple clinic visits and join a separate long-term follow-up study for ongoing safety monitoring up to 15 years post-TAK-007 administration.
DelveInsight's NK Cell Therapies Pipeline report showcases a dynamic field with over 140 active contributors developing more than 160 pipeline treatments for NK Cell Therapies care.
The top NK Cell Therapies Companies include Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and others.
Promising NK Cell Therapies Pipeline Therapies include Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

Stay updated with the latest pipeline overview for NK Cell Therapies. Gain insights into clinical trials, emerging treatments, and key companies via DelveInsight @ NK Cell Therapies Treatment Drugs

Natural Killer Cell therapy Emerging Drugs Profile

Bemarituzumab: Amgen Bemarituzumab is a pioneering, isoform-specific, humanized monoclonal antibody in development as a precision immunotherapy for tumors overexpressing FGFR2b, a variant of a receptor for certain fibroblast growth factor (FGF) family members. Bemarituzumab inhibits FGFs 7, 10, and 22 from attaching to FGFR2b, and is designed for improved antibody-dependent cell-mediated cytotoxicity (ADCC) to boost direct tumor destruction by mobilizing natural killer (NK) cells. Recent clinical data indicate that bemarituzumab's selectivity sidesteps the limiting side effects seen with broader pan-FGFR tyrosine kinase inhibitors targeting multiple FGFRs, including FGFR2. In December 2017, Five Prime and Zai Lab formed a partnership for bemarituzumab's development and commercialization in Greater China. The drug is currently in Phase III trials for Gastric and Gastroesophageal Junction (GEJ) Cancers.
Monalizumab: Innate Pharma Monalizumab (IPH2201) is a potentially groundbreaking immune checkpoint blocker targeting NKG2A receptors on tumor-infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A acts as an inhibitory receptor for HLA-E, which tumors often overproduce to shield from NKG2A+ immune cells. By disrupting this blockade, monalizumab enables HLA-E-expressing cancer cells to be detected by the immune system. This restores widespread anti-tumor activity driven by NK and T cells, amplifying the potency of other therapeutic antibodies. Through its impact on both innate and adaptive immunity, monalizumab shows potential for reigniting responses against diverse solid tumors and blood cancers. The drug is in Phase III for Unresectable Stage III Non-small Cell Lung Cancer and Phase II for Neoadjuvant NSCLC, along with other malignancies.
L1 t-haNK: ImmunityBio PD-L1.t-haNK cells are a human-sourced, allogeneic, natural killer cell line modified to express a chimeric antigen receptor (CAR) against PD-L1, derived from NantKwest's proprietary NK-92 (aNK) master cell line. Beyond PD-L1 targeting, PD-L1.t-haNK is engineered to generate internal IL-2 for superior CD16-mediated antibody-dependent cellular cytotoxicity. The drug is in Phase II clinical studies for gastric cancer, pancreatic cancer, squamous cell cancer, glioblastoma, and non-small cell lung cancer.
M ceNK: ImmunityBio The innovative, memory cytokine-enriched Natural Killer (m-ceNK) cells are the patient's own NK cells boosted with cytokines, including ImmunityBio's IL-15 super agonist Anktiva (N-803). These m-ceNK cells, or memory-cytokine enriched NK cells, are formulated for autologous cell therapy but also available as an allogeneic version from cord blood. M-ceNK offers clinical advantages due to its simplicity and potential for outpatient use. ImmunityBio has effectively enriched and multiplied donor natural killer cells from peripheral blood via apheresis, creating a distinctive NK cell type with high killing power, interferon-gamma output, and memory-like properties. M-ceNK cells are in Phase I for Solid Tumors. The company is also exploring M-ceNK in Phase II for Acute Myeloid Leukemia (AML) and Ovarian cancer, though specifics are pending.
DF6002: Dragonfly Therapeutics DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein aimed at delivering potent anti-tumor effects by fostering an inflammatory tumor environment essential for effective immune responses. DF6002, Dragonfly's prolonged half-life IL12 cytokine, is an experimental immunotherapy tested in adults with advanced solid tumors. DF6002 may trigger robust anti-tumor immunity in patients ineligible or unresponsive to existing treatments. The drug is in Phase I/II development for solid tumors.
oNKord: Glycostem Therapeutics Allogeneic Natural Killer Cell Therapy (known as oNKord) involves natural killer cells (NK-cells) produced ex vivo from umbilical cord blood stem cells. The production method is highly efficient, achieving a 5-10,000 fold expansion. The resulting cells are over 95% pure, free of T- and B-cell contaminants, pre-activated, and primed to combat cancer. As per Glycostem, oNKord can address conditions like Multiple Myeloma, blood cancers, and solid tumors including colorectal, head-neck, lung, and breast cancer. The drug is in Phase I/II trials for acute myeloid leukemia (AML).
KUR-501: Athenex KUR-501 is an autologous cell therapy utilizing Cell Medica's natural killer T (NKT) cell platform with engineered chimeric antigen receptors (CARs) and IL-15 secretion to maintain cell function in hostile tumor settings. CAR.GD2-IL-15 NKTs are GD2-targeted chimeric antigen receptor (CAR) and Interleukin-15 producing autologous natural killer T-cells. The construct includes genes for a chimeric antigen receptor from the 14g2a antibody recognizing GD2 on neuroblastoma cells (GD2-CAR), plus a CD28 segment for longevity, and an IL-15 gene. This trio maximized anti-tumor effects and cell persistence in preclinical models. Athenex is running a Phase I trial with Baylor College of Medicine (BCM) in pediatric patients for neuroblastoma.

The NK Cell Therapies Pipeline Report Provides Insights into

The report delivers comprehensive details on firms advancing therapies for NK Cell Therapies, including the cumulative treatments each company is pursuing.
It reviews diverse therapeutic candidates categorized into initial, intermediate, and advanced development stages for NK Cell Therapies management.
NK Cell Therapies Companies are focused on precision therapeutics with ongoing and paused (inactive or terminated) programs.
NK Cell Therapies Drugs in development, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.
Comprehensive examination of partnerships (business alliances and academic ties), licensing arrangements, and funding details to propel future progress in the NK Cell Therapies market.

Explore innovative treatments and clinical trials in the NK Cell Therapies Pipeline. Obtain DelveInsight's detailed report today! @ New NK Cell Therapies Drugs

NK Cell Therapies Companies Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and others.

NK Cell Therapy pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

Oral
Intravenous
Subcutaneous
Parenteral
Topical

NK Cell Therapies Products have been categorized under various Molecule types such as

Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule

Reveal the future of NK Cell Therapies Treatment. Learn about emerging NK Cell Therapies Marketed and Drugs Developments, and key companies with DelveInsight's expert analysis @ NK Cell Therapies Market Drivers and Barriers

Scope of the NK Cell Therapies Pipeline Report

Coverage- Global
NK Cell Therapies Companies- Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and others.
NK Cell Therapies Pipeline Therapies- Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.
NK Cell Therapies Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
NK Cell Therapies Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NK Cell Therapies and clinical trials. Download DelveInsight's in-depth pipeline report now! @ NK Cell Therapies Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Natural Killer (NK) cell therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Bemarituzumab: Amgen
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)
L1 t-haNK: ImmunityBio
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
KUR-501: Athenex
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report.....
Inactive Products
Natural Killer (NK) cell therapy Key Companies
Natural Killer (NK) cell therapy Key Products
Natural Killer (NK) cell therapy- Unmet Needs
Natural Killer (NK) cell therapy- Market Drivers and Barriers
Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
Natural Killer (NK) cell therapy Analyst Views
Natural Killer (NK) cell therapy Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Kanishk

kkumar@delveinsight.com

https://kkumar.exblog.jp/244742301/

https://www.japanesewomenorg.com/read-blog/62344

https://medium.com/@kanishkkumar.kumar2580/menas-healthcare-shift-generics-and-biologics-in-focus-0850d1119dfa

https://kanishk009.blogspot.com/2025/11/transforming-patient-care-generics-and.html

https://connect.usama.dev/blogs/49204/Generics-vs-Biologics-Trends-in-Middle-Eastern-Healthcare

https://gracebook.app/blogs/101308/Biologics-and-Generics-Driving-Healthcare-Innovation-in-MENA

https://shareyoursocial.com/read-blog/89817

https://friends-social.com/blogs/81931/MENA-Healthcare-Transformation-Through-Generics-and-Biologics

https://kkumar.hatenablog.com/entry/2025/11/10/172847

https://logcla.com/blogs/1004454/The-Future-of-Medicine-in-MENA-Generics-and-Biologics